

Enzymatic Therapy

NATURAL MEDICINES®

November 12, 2003

1307 104 100-011832

DEC - 1 2003

Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 810
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDIENT(S) TO WHICH THE CLAIM REFERS</u>
Vitaline® Vitamin B-Complex 100	The B vitamins in Complex 100 assist in cell growth and support energy metabolism.* Complex 100, which includes niacinamide, thiamin, riboflavin, folic acid, vitamin B6, vitamin B12, pantothenic acid, and choline, is especially important for support of energy production and mental function.*	Thiamin, Riboflavin, Niacin (as niacinamide), Vitamin B-6, Folic Acid, Vitamin B-12, Pantothenic Acid

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: _____

Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: _____

11/12/03

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

975 0162


LET

13413

Vitaline B-Complex 100 1e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael P. Devereux". The signature is written in a cursive style with a large, stylized initial "M".

Michael P. Devereux
Chief Financial Officer